null - FindTrial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223719

Enrollment

200

Registered

2017-11-16

Start date

2015-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : Avelumab INN of investigational material : avelumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
safety efficacy Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1	—

Secondary

Measure	Time frame
safety efficacy Duration of Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results